steve broadbent - what is a reasonably likely surrogate? what is its use in pkd drug development?
Published 4 years ago • 12 plays • Length 1:49Download video MP4
Download video MP3
Similar videos
-
0:56
steve broadbent - what has c-path done to accelerate therapies for pkd?
-
1:02
steve broadbent - how has qualifying total kidney volume helped in pkd therapy development?
-
9:55
3.2 - what is a disease? vulnerable to robust
-
5:58
how healthcare rcm drives hospital's mission - covenant health's stephen grubbs
-
42:42
adaptive dose finding using toxicity probability intervals - neby bekele
-
34:19
professor steven weisbord - trials and tribulations in aki. do we know where we are going?
-
1:01:07
the future of healthcare: revenue cycle management strategies for the 'new normal'
-
54:56
andrew ward: "understanding the structure of the virus" (11/17/21)
-
1:04:43
susan athey and stefan wager: estimating heterogeneous treatment effects in r
-
7:29
chapter 3 : the impact of stroke
-
10:27
richard ostfeld | vector borne disease ecology
-
8:46
covid-19 symposium: virus structure-transmission patterns | dr. frederic bushman
-
1:39
keep antibiotics working: a patient’s perspective
-
2:28
predicting your risk of illness
-
8:33
trusting antibody testing: coronavirus pandemic—daily report with rishi desai, md, mph
-
7:05
what are the risks and benefits of volunteering for a clinical trial?
-
12:07
lee spetner takes aim at darwin, malthus and antibiotic resistant...
-
6:11
process vs procedure: what's the difference?
-
6:12
#32 sick building syndrom (sbs)
-
7:56
gluten’s relationship to serious disease & early detection”
-
2:23
scarborough health network: transforming mental health through clinical standardization